For example, MiNA Therapeutics is one of the several biotech companies which have started to harness the mechanisms of sRNA-mediated gene regulation to develop anti-cancer therapies, and has recently initiated a phase II clinical trial to test sRNAs directed to CCAAT/enhancer-binding protein-α (CEBPA), a transcription factor that regulates myeloid cell development. This evidence concerns the gene CEBPA and cancer.